Please use this identifier to cite or link to this item: https://doi.org/10.1186/1745-6215-12-4
Title: International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: Rationale and protocol
Authors: Williams, L.M.
Rush, A.J. 
Koslow, S.H.
Wisniewski, S.R.
Cooper, N.J.
Nemeroff, C.B.
Schatzberg, A.F.
Gordon, E.
Issue Date: 5-Jan-2011
Citation: Williams, L.M., Rush, A.J., Koslow, S.H., Wisniewski, S.R., Cooper, N.J., Nemeroff, C.B., Schatzberg, A.F., Gordon, E. (2011-01-05). International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: Rationale and protocol. Trials 12 : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1745-6215-12-4
Abstract: Background: Clinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators.Methods/Design: The International Study to Predict Optimized Treatment - in Depression (iSPOT-D) is a multi-centre, international, randomized, prospective, open-label trial. It is enrolling 2016 MDD outpatients (ages 18-65) from primary or specialty care practices (672 per treatment arm; 672 age-, sex- and education-matched healthy controls). Study-eligible patients are antidepressant medication (ADM) naïve or willing to undergo a one-week wash-out of any non-protocol ADM, and cannot have had an inadequate response to protocol ADM. Baseline assessments include symptoms; distress; daily function; cognitive performance; electroencephalogram and event-related potentials; heart rate and genetic measures. A subset of these baseline assessments are repeated after eight weeks of treatment. Outcomes include the 17-item Hamilton Rating Scale for Depression (primary) and self-reported depressive symptoms, social functioning, quality of life, emotional regulation, and side-effect burden (secondary). Participants may then enter a naturalistic telephone follow-up at weeks 12, 16, 24 and 52. The first half of the sample will be used to identify potential predictors and moderators, and the second half to replicate and confirm.Discussion: First enrolment was in December 2008, and is ongoing. iSPOT-D evaluates clinical and biological predictors of treatment response in the largest known sample of MDD collected worldwide.Trial registration: International Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov Identifier: NCT00693849. URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment+for+Depression&rank=1. © 2011 Williams et al; licensee BioMed Central Ltd.
Source Title: Trials
URI: http://scholarbank.nus.edu.sg/handle/10635/110141
ISSN: 17456215
DOI: 10.1186/1745-6215-12-4
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

139
checked on Nov 21, 2022

WEB OF SCIENCETM
Citations

137
checked on Nov 21, 2022

Page view(s)

157
checked on Nov 24, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.